Gilead Sciences, Inc. and Kite Pharma, Inc announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash.
Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.
TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced financial and company results for the second quarter of 2017.
TraceLink Inc., the world’s largest track and trace network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced that it has acquired ROC IT Solutions, the leader in intelligent edge data capture for serialized product inventory in the pharmaceutical supply chain.
Valeant Pharmaceuticals International, Inc announced that certain affiliates of the Company have entered into an agreement to sell its Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. Limited partners of the Fund include industry veterans in other geographic markets, such as China Regenerative Medicine International Limited .
Medicure Inc , a leading Canadian specialty pharmaceutical company, is pleased to announce that it has closed the acquisition of additional interests in Apicore Inc. and Apicore LLC (together "Apicore") from Apicore's founding shareholders as previously announced on July 10, 2017.
Valeant Pharmaceuticals International, Inc. announced that its affiliate has completed the sale of all of the outstanding equity interests in its former subsidiary Dendreon Pharmaceuticals LLC to the Sanpower Group, Co., Ltd. , for $819.9 million in cash.